Technical Analysis for CTLT - Catalent Inc

Grade Last Price % Change Price Change
D 109.04 -0.31% -0.3400
CTLT closed down 0.31 percent on Tuesday, April 13, 2021, on 1.11 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical CTLT trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.31%
Pocket Pivot Bullish Swing Setup -0.31%
Up 3 Days in a Row Strength -0.31%
Shooting Star Candlestick Bearish 1.51%
Narrow Range Bar Range Contraction 1.51%
NR7 Range Contraction 1.51%
Older End-of-Day Signals for CTLT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 24 hours ago
10 DMA Support about 24 hours ago
Down 1 ATR about 24 hours ago
Gapped Down (Full) about 24 hours ago
Down 3% about 24 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Catalent Inc Description

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain clinical supply services. The company serves pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients; a collaboration with the Janssen Pharmaceutical Companies, as well as Ennaid Therapeutics; a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19; and has collaboration with Moderna, Inc. for manufacturing mRNA-based COVID-19 vaccine candidate. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.


Classification

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Keywords: Manufacturing Biotechnology Partnership Pharmaceutical Industry Biopharmaceutical Life Sciences Pharmacology Dietary Supplement Dietary Supplements Dosage Forms Drug Delivery Pharmaceutical Companies Prescription Drug Molecules Ophthalmic Inventory Management Drug Product Animal Health Products Delivery Technologies Gene Therapy Small Molecules Rare Disease Capsule Development Solution Ftg Specialty Drugs In The United States Clinical And Commercial Manufacturing Softgel

Is CTLT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 127.64
52 Week Low 74.44
Average Volume 1,006,647
200-Day Moving Average 0.0000
50-Day Moving Average 110.1256
20-Day Moving Average 105.8440
10-Day Moving Average 106.9460
Average True Range 3.2113
ADX 13.36
+DI 23.2749
-DI 25.0313
Chandelier Exit (Long, 3 ATRs ) 102.4111
Chandelier Exit (Short, 3 ATRs ) 109.7139
Upper Bollinger Band 110.5985
Lower Bollinger Band 101.0895
Percent B (%b) 0.84
BandWidth 8.9840
MACD Line 0.1224
MACD Signal Line -0.6422
MACD Histogram 0.7647
Fundamentals Value
Market Cap 17.96 Billion
Num Shares 165 Million
EPS 1.58
Price-to-Earnings (P/E) Ratio 68.93
Price-to-Sales 4.61
Price-to-Book 5.13
PEG Ratio 3.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 115.3400
Resistance 3 (R3) 114.6933 111.9467 114.2900
Resistance 2 (R2) 111.9467 110.3423 112.2700 113.9397
Resistance 1 (R1) 110.4933 109.3511 111.2200 111.1400 113.5899
Pivot Point 107.7467 107.7467 108.1100 108.0700 107.7467
Support 1 (S1) 106.2933 106.1423 107.0200 106.9400 104.4901
Support 2 (S2) 103.5467 105.1511 103.8700 104.1403
Support 3 (S3) 102.0933 103.5467 103.7900
Support 4 (S4) 102.7400